Author:
Borkar Pradnya S.,Balpande Vijaya P.,Mahajan Anjali R.
Reference10 articles.
1. D. Castanotto, J.J. Rossi, The promises and pitfalls of RNA interference based therapeutics. Nature 457(7228), 426–433 (2009)
2. R. Osborne, Companies jostle for lead in RNAi, despite uncertainties. Nat. Biotechnol. 25(11), 1191–1192 (2007)
3. D. Thomas, S. Frank, RNAi and microRNA-oriented therapy in cancer: rationales, pomises and challenges. J. Curr. Oncol. 16(4), 61–66 (2009)
4. E. Buratti, A. Dhir, M.A. Lewandowska, F.E. Baralle, RNA structure is a key regulatory element in pathological ATM and CFTR pseudoexon inclusion events. Nucleic Acids Res. 35(13), 4369–4383 (2007)
5. J. Reeder, P. Steffen, R. Giegerich, pknotsRG: RNA pseudoknot folding including near-optimal structures and sliding windows. Nucleic. Acid. Res. 35(Web Server issue), W320 (2007)